⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
WOCKPHARMA - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.2
| Stock Code | WOCKPHARMA | Market Cap | 19,805 Cr. | Current Price | 1,219 ₹ | High / Low | 1,870 ₹ |
| Stock P/E | 98.5 | Book Value | 178 ₹ | Dividend Yield | 0.00 % | ROCE | 4.40 % |
| ROE | -0.53 % | Face Value | 5.00 ₹ | DMA 50 | 1,339 ₹ | DMA 200 | 1,380 ₹ |
| Chg in FII Hold | -0.10 % | Chg in DII Hold | -0.45 % | PAT Qtr | 38.0 Cr. | PAT Prev Qtr | 54.0 Cr. |
| RSI | 35.0 | MACD | -44.0 | Volume | 4,41,631 | Avg Vol 1Wk | 5,94,732 |
| Low price | 1,154 ₹ | High price | 1,870 ₹ | PEG Ratio | 4.08 | Debt to equity | 0.76 |
| 52w Index | 8.96 % | Qtr Profit Var | 273 % | EPS | 11.8 ₹ | Industry PE | 27.6 |
📊 Financial Overview
- Revenue & Profitability: Quarterly PAT declined from 54 Cr. to 38 Cr., showing earnings pressure. EPS at 11.8 ₹ is modest.
- Margins & Returns: ROCE at 4.40% is weak, and ROE at -0.53% indicates negative shareholder returns.
- Debt: Debt-to-equity ratio of 0.76 is relatively high, raising leverage concerns.
- Cash Flow: Weak profitability and high debt may strain liquidity.
💹 Valuation
- P/E Ratio: 98.5 vs Industry PE of 27.6 → Significantly overvalued relative to peers.
- P/B Ratio: Current Price 1,219 ₹ vs Book Value 178 ₹ → High premium.
- PEG Ratio: 4.08 → Expensive relative to growth prospects.
- Intrinsic Value: Current price trades above fair value, limited margin of safety.
🏢 Business Model & Competitive Advantage
- Pharmaceutical company with diversified product portfolio.
- Global presence provides scale, but profitability remains weak.
- High debt and low efficiency metrics reduce competitive strength.
📈 Technicals & Entry Zone
- RSI at 35.0 → Near oversold territory, potential accumulation zone.
- MACD negative (-44.0) → Weak momentum, short-term caution advised.
- Entry Zone: Attractive accumulation between 1,150–1,200 ₹.
- Long-Term Holding: Risky due to weak fundamentals; suitable only for speculative investors.
✅ Positive
- EPS at 11.8 ₹ provides some valuation support.
- 52-week performance up 8.96%, showing resilience despite volatility.
- Global presence in pharmaceuticals provides scale advantage.
⚠️ Limitation
- High P/E and PEG ratios suggest overvaluation.
- ROCE and ROE are weak, highlighting poor efficiency.
- Debt-to-equity ratio of 0.76 raises financial risk.
📉 Company Negative News
- Quarterly PAT declined from 54 Cr. to 38 Cr.
- FII holdings decreased by 0.10% and DII holdings by 0.45%, showing reduced institutional confidence.
📈 Company Positive News
- EPS at 11.8 ₹ provides some valuation strength.
- RSI indicates oversold levels, offering accumulation opportunity.
🏭 Industry
- Industry PE at 27.6 suggests sector trades at lower multiples.
- WOCKPHARMA commands premium valuation despite weak fundamentals, driven by speculative interest.
🔎 Conclusion
WOCKPHARMA shows resilience with global presence but suffers from weak profitability, high debt, and overvaluation compared to industry peers. Entry is favorable near 1,150–1,200 ₹ for speculative investors, but long-term holding carries significant risk due to poor ROE/ROCE and earnings pressure. Conservative investors should avoid until fundamentals improve.